Tag: Solve Therapeutics

Solve Therapeutics has filed a notice of an exempt offering of securities to raise $120,535,618.00 in New Funding.

Solve Therapeutics has filed a notice of an exempt offering of securities to raise $120,535,618.00 in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Solve Therapeutics, Inc. is raising up to $120,535,618.00 in new funding. The federal securities law requires the notice to be filed by companies that have…

Read More Read More

Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors

Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors

Financing accelerates development of clinical-stage assets SLV-154 and SLV‑324, both featuring Solve’s CloakLink™ linker technology Funding round was led by Yosemite, with participation from new investors Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management,…

Read More Read More